Stocktoria
Burning Rock Biotech Ltd BNR
Nasdaq · XNAS · stock · Services-Medical Laboratories · website · IPO 2020-06-12
Burning Rock Biotech Ltd statistics & valuation
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Gross margin | 74.7% | 70.3% | 67.6% | 67.5% | 71.7% |
| Operating margin | -10.2% | -69.3% | -124.5% | -174.1% | -156.9% |
| Net margin | -10.3% | -67.2% | -121.6% | -172.4% | -156.9% |
| FCF margin | -6.2% | -18.9% | -49.1% | -92.1% | -134.3% |
| Return on assets | -6.7% | -39.2% | -62.9% | -61.2% | -35.0% |
| Return on equity | -10.3% | -59.7% | -85.1% | -83.8% | -43.2% |
| Current ratio | 2.99 | 2.92 | 3.36 | 3.06 | 4.89 |
| Revenue growth | 9.2% | -6.6% | -7.3% | 2.5% | 21.0% |
Source: SEC EDGAR filings · CIK 0001792267 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.